Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 13631
Country/Region: Côte d'Ivoire
Year: 2016
Main Partner: Ariel Glaser Pediatric AIDS Healthcare Initiative
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $5,769,250 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $555,682
Care: Orphans and Vulnerable Children (HKID) $690,503
Care: TB/HIV (HVTB) $454,205
Care: Pediatric Care and Support (PDCS) $94,602
Laboratory Infrastructure (HLAB) $32,000
Testing: HIV Testing and Counseling (HVCT) $236,216
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $570,095
Treatment: Adult Treatment (HTXS) $2,770,696
Treatment: Pediatric Treatment (PDTX) $365,251
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: 10-14 Female 2017 11
GEND_GBV Age/Sex: 15-19 Female 2017 14
GEND_GBV Age/Sex: 20-24 Female 2017 27
GEND_GBV Age/Sex: 25-49 Female 2017 127
GEND_GBV Age/Sex: 50+ Female 2017 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 46
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 122
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 58
GEND_GBV Number of people receiving post-GBV care 2017 180
GEND_GBV Sum of Age/Sex Disaggregates 2017 11
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 8,187
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 8,788
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 75,762
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 81,573
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 174,310
HTS_TST Service Delivery Point (Community): Index testing 2017 948
HTS_TST Service Delivery Point (Community): Other 2017 2,833
HTS_TST Service Delivery Point (Facility): Inpatient 2017 71,835
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 1,436
HTS_TST Service Delivery Point (Facility): Outpatient 2017 8,447
HTS_TST Service Delivery Point (Facility): PMTCT 2017 82,768
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 6,043
HTS_TST Sum of Aggregated Age/Sex <15 2017 16,975
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 157,335
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 174,310
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 487
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 490
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 3,095
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,342
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 3
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 23
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 28
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 13
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 13
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 27
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 2
OVC_SERV Age/Sex: 18+ Female 2017 2,659
OVC_SERV Age/Sex: 18+ Male 2017 1,335
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 4,147
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 3,859
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 12,000
OVC_SERV Sum of Age/Sex disaggregates 2017 3,994
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,010
PMTCT_ART New on ART 2017 1,292
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 84,027
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,300
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 678
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 52
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 32
PMTCT_EID Sum of Infant Age disaggregates 2017 1,978
PMTCT_STAT By: Known positives at entry 2017 1,010
PMTCT_STAT By: Number of new positives identified 2017 1,390
PMTCT_STAT Number of new ANC and L&D clients 2017 88,394
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 84,027
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,400
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 23
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 879
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 19
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 712
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,718
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,633
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,817
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 430
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,920
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 467
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,817
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 26,220
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 10,243
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 957
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 974
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 38,385
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 100
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,178
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 181
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,584
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 6,043
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 6,397
TX_CURR Age/Sex: <1 2017 268
TX_CURR Age/Sex: <1-9 2017 1,431
TX_CURR Age/Sex: 10-14 Female 2017 314
TX_CURR Age/Sex: 10-14 Male 2017 336
TX_CURR Age/Sex: 15-19 Female 2017 398
TX_CURR Age/Sex: 15-19 Male 2017 145
TX_CURR Age/Sex: 20-24 Female 2017 1,704
TX_CURR Age/Sex: 20-24 Male 2017 331
TX_CURR Age/Sex: 25-49 Female 2017 21,863
TX_CURR Age/Sex: 25-49 Male 2017 10,159
TX_CURR Age/Sex: 50+ Female 2017 2,839
TX_CURR Age/Sex: 50+ Male 2017 2,868
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,153
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,196
TX_CURR Aggregated Age/Sex: 15+ Female 2017 26,804
TX_CURR Aggregated Age/Sex: 15+ Male 2017 13,503
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 42,656
TX_CURR Sum of age/sex disaggregates 2017 543
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,349
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 40,307
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 42,656
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 412
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 431
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 7,311
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,905
TX_NEW By Age/Sex: <1 2017 91
TX_NEW By Age/Sex: 1-9 2017 514
TX_NEW By Age/Sex: 10-14 Female 2017 111
TX_NEW By Age/Sex: 10-14 Male 2017 127
TX_NEW By Age/Sex: 15-19 Female 2017 102
TX_NEW By Age/Sex: 15-19 Male 2017 102
TX_NEW By Age/Sex: 20-24 Female 2017 424
TX_NEW By Age/Sex: 20-24 Male 2017 102
TX_NEW By Age/Sex: 25-49 Female 2017 5,967
TX_NEW By Age/Sex: 25-49 Male 2017 2,770
TX_NEW By Age/Sex: 50+ Female 2017 818
TX_NEW By Age/Sex: 50+ Male 2017 931
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 12,059
TX_NEW Sum of Age/Sex disaggregates 2017 11,454
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 12,059
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 44,686
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 33,474
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 883
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 906
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 21,075
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 10,610
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,183
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,208
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 28,137
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 14,158
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 35
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 235
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 46
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 49
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 73
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 19
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 318
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 59
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,110
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,900
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 560
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 590
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 178
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 187
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,056
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,568
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 7,996
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 9,993
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 45
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 306
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 66
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 96
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 400
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 77
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,141
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,380
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 681
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 708
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 236
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 245
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,289
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,205
Cross Cutting Budget Categories and Known Amounts Total: $1,252,777
Food and Nutrition: Policy, Tools, and Service Delivery $120,000
Human Resources for Health $1,132,777